Intervention
Pertuzumab
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 176 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownNeoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBCNCT07797218 · 2026-07-01
RECRUITINGDalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast CancerNCT07610720 · 2026-06-01
RECRUITINGElacestrant in Advanced Triple Positive Breast CancerNCT07612215 · 2026-05-13
RECRUITINGA Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast CancerNCT07518173 · 2026-04-21
RECRUITINGOptimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast CancerNCT07402473 · 2026-03-26
RECRUITINGA Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerNCT07441460 · 2026-03-06
RECRUITINGTrastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity ManagementNCT07371585 · 2026-02-18
RECRUITINGIBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast CancerNCT07377643 · 2026-02-10
RECRUITINGNeoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast CancerNCT07393425 · 2026-02-02
RECRUITINGNeoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast CancerNCT07340398 · 2025-12-25
RECRUITINGPh2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR TrialNCT07407920 · 2025-10-09
RECRUITINGA Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerNCT07102381 · 2025-09-24
RECRUITINGShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabNCT06876714 · 2025-09-17
RECRUITINGA Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerNCT06891833 · 2025-06-05
RECRUITINGSHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BCNCT06927180 · 2025-04-16
RECRUITINGStudy of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)NCT06686394 · 2025-02-26
RECRUITINGBRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast CancerNCT06441890 · 2024-12-05
RECRUITINGThe SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerNCT06439693 · 2024-08-08
RECRUITINGNeoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 StudyNCT06162559 · 2023-12-18
RECRUITINGShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast CancerNCT05891561 · 2023-11-01
RECRUITINGTrastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast CancerNCT05900206 · 2023-10-26
RECRUITINGTrilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant ChemotherapyNCT05978648 · 2023-09-20
RECRUITINGDisitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical TrialNCT06278870 · 2023-09-06
RECRUITINGEfficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.NCT05838066 · 2023-07-23
RECRUITINGEC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast CancerNCT05883852 · 2023-06-07
RECRUITINGCorrelation of Clinical Response to Pathologic Response in Patients With Early Breast CancerNCT05020860 · 2023-04-18
RECRUITINGDETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating MutationsNCT05786716 · 2023-03-07
RECRUITINGPyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast CancerNCT05638594 · 2022-12-20
RECRUITINGFudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyNCT05582499 · 2022-11-01
RECRUITINGA Study for the Adjuvant Treatment of Breast CancerNCT05420467 · 2022-07-10
RECRUITINGA Study for the Neoadjuvant Treatment of Breast CancerNCT05420454 · 2022-07-10
RECRUITINGConcurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast CancerNCT04329065 · 2022-04-20
RECRUITINGStudy of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & PertuzumabNCT05325632 · 2021-10-28
RECRUITINGSafety of Continuing HER-2 Directed Therapy in Overt Left Ventricular DysfunctionNCT04680442 · 2021-07-01
RECRUITINGCirculating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast CancerNCT04993014 · 2021-03-01
RECRUITINGAdding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisNCT07578116 · 2027-03-09
NOT_YET_RECRUITINGTrial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast CancerNCT07772245 · 2026-12-31
NOT_YET_RECRUITINGRoll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.NCT07679269 · 2026-12-15
NOT_YET_RECRUITINGSHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete ResponseNCT07856303 · 2026-10-01
NOT_YET_RECRUITINGFulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast CancerNCT07716046 · 2026-10-01
NOT_YET_RECRUITINGT-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdNCT07683754 · 2026-09-04
NOT_YET_RECRUITINGTrastuzumab/Pertuzumab With Fulvestrant and Kurmoxilil in HR+/HER2+ Early Breast CancerNCT07857226 · 2026-09-01
NOT_YET_RECRUITINGA Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast CancerNCT07545044 · 2026-05-30
NOT_YET_RECRUITINGNeoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.NCT07528898 · 2026-05-01
NOT_YET_RECRUITINGOptimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular ImagingNCT07527806 · 2026-05-01
NOT_YET_RECRUITINGPhase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)NCT07565324 · 2026-04-30
NOT_YET_RECRUITINGPyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast CancerNCT07470203 · 2026-03-31
NOT_YET_RECRUITINGIdentification of HER2-Positive Breast Cancer Molecular Characterization and SubtypesNCT07187752 · 2025-09-30
NOT_YET_RECRUITINGHB1801 Combined Treatment of HER2-positive Breast CancerNCT07116824 · 2025-09-15
NOT_YET_RECRUITINGFeasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast CancerNCT04419181 · 2025-08-11
WITHDRAWNTrastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BCNCT07047755 · 2025-07-01
NOT_YET_RECRUITINGA Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast CancerNCT06747338 · 2024-12-16
ACTIVE_NOT_RECRUITINGNeoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)NCT06510465 · 2024-08-01
NOT_YET_RECRUITINGA Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerNCT06445400 · 2024-06-19
ACTIVE_NOT_RECRUITINGTrial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast CancerNCT05954143 · 2023-11-30
TERMINATEDStudy of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast CancerNCT05983094 · 2023-09-01
NOT_YET_RECRUITINGDe-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast CancerNCT07421141 · 2023-09-01
ACTIVE_NOT_RECRUITINGSecondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of TucatinibNCT05323955 · 2023-03-23
ACTIVE_NOT_RECRUITINGSMMART Adaptive Clinical Treatment (ACT) TrialNCT05238831 · 2023-01-30
WITHDRAWNStudy to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast CancerNCT05720026 · 2023-01-09
UNKNOWNCommon conditions
Breast Cancer75HER2-positive Breast Cancer36Breast Neoplasms13Metastatic Breast Cancer10Advanced Breast Cancer5Anatomic Stage II Breast Cancer AJCC v85Anatomic Stage IV Breast Cancer AJCC v85Breast Cancer Female4HER2 Positive Breast Cancer4Anatomic Stage I Breast Cancer AJCC v83Anatomic Stage III Breast Cancer AJCC v83HER2-Positive Metastatic Breast Cancer3Metastatic Breast Carcinoma3Metastatic HER2-Positive Breast Carcinoma3Non-Small Cell Lung Cancer3Recurrent Breast Carcinoma3Stage II Breast Cancer3Stage III Breast Cancer AJCC v73Stage IIIA Breast Cancer AJCC v73Stage IIIB Breast Cancer AJCC v73Stage IIIC Breast Cancer AJCC v73Advanced Malignant Solid Neoplasm2Anatomic Stage IIA Breast Cancer AJCC v82Anatomic Stage IIB Breast Cancer AJCC v82Anatomic Stage IIIA Breast Cancer AJCC v82
Leading sponsors
Hoffmann-La Roche25Dana-Farber Cancer Institute6Fudan University6Genentech, Inc.6National Cancer Institute (NCI)5Second Affiliated Hospital, Zhejiang University, School of Medicine5H. Lee Moffitt Cancer Center and Research Institute4Shanghai Jiao Tong University School of Medicine4Shanghai JMT-Bio Inc.4AstraZeneca3Sichuan Baili Pharmaceutical Co., Ltd.3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.2Eli Lilly and Company2Fondazione Michelangelo2GBG Forschungs GmbH2
Trial status mix
COMPLETED59
RECRUITING35
ACTIVE_NOT_RECRUITING34
NOT_YET_RECRUITING17
TERMINATED14
UNKNOWN14
WITHDRAWN3
Phase mix
PHASE2108
PHASE343
PHASE129
PHASE44
NA3
EARLY_PHASE11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.